JDOC news

JPMorgan Healthcare Leaders · Healthcare

Stories about this fund's companies, ranked by fund weight and recency. Times are local.

Quartz · 28 Oct 2026, 16:16 UTC
Best-selling drugs 2026: 7 of the top 10 by 2025 sales
18.8% of JDOC
Yahoo! Finance · 28 Oct 2026, 07:29 UTC
The Zacks Analyst Blog Highlights Eli Lilly, Novartis, Johnson & Johnson and AbbVie
22.0% of JDOC
Seeking Alpha · 28 Oct 2026, 15:55 UTC
Pharma giants Merck, Eli Lilly face earnings health check (MRK:NYSE) | Seeking Alpha
12.6% of JDOC
24/7 Wall St. · 28 Oct 2026, 12:14 UTC
3 Big Pharma Earnings Reports to Watch: Eli Lilly, Merck and Gilead
12.6% of JDOC
Where to buy JDOC
- [Broker A]Visit ↗
- [Broker B]Visit ↗
[Affiliate and risk wording from the law firm]
Quartz · 28 Oct 2026, 14:15 UTC
New weight-loss drugs: what 6 drugmakers are testing
10.4% of JDOC
Benzinga · 28 Oct 2026, 19:32 UTC
Traders Are Pricing a 7% Swing in Amazon Ahead of Earnings - Amazon.com (NASDAQ:AMZN), Intel (NASDAQ:INTC
8.4% of JDOC
Where to buy JDOC
- [Broker A]Visit ↗
- [Broker B]Visit ↗
[Affiliate and risk wording from the law firm]
24/7 Wall St. · 28 Oct 2026, 19:24 UTC
16% of Employers Are Thinking About Cutting Weight-Loss Drug Coverage
7.8% of JDOC
Yahoo! Finance · 28 Oct 2026, 16:03 UTC
This Dividend Powerhouse Is Heading Into Q3 Earnings With Plenty at Stake
7.8% of JDOC
Yahoo! Finance · 27 Oct 2026, 13:47 UTC
What's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings?
16.2% of JDOC
Benzinga · 28 Oct 2026, 13:25 UTC
Eli Lilly Says Retatrutide Delivers More Than Double Ozempic's Weight Loss in Late-Stage Diabetes Trial -
7.8% of JDOC
Yahoo! Finance · 27 Oct 2026, 15:16 UTC
4 Arthritis Drug Stocks Investors Should Monitor for Growth Potential
14.2% of JDOC
Market Screener · 28 Oct 2026, 12:07 UTC
Eli Lilly And Company Announces Positive Topline Results From TRANSCEND-T2D-2 Phase 3 Trial Of Retatrutide In Adults With Type 2 Diabetes
7.8% of JDOC
Benzinga · 28 Oct 2026, 10:04 UTC
Top Wall Street Forecasters Revamp Eli Lilly Expectations Ahead Of Q3 Earnings - Eli Lilly (NYSE:LLY)
7.8% of JDOC
www.theepochtimes.com · 28 Oct 2026, 00:00 UTC
Judge Declines to Block Eli Lilly Weight-Loss Drug Ads in Dispute With Novo Nordisk
10.4% of JDOC
Quartz · 28 Oct 2026, 12:37 UTC
10 Medicare Advantage insurer ratings for 2027 across 4 categories
7.0% of JDOC
Seeking Alpha · 28 Oct 2026, 08:28 UTC
AbbVie: Still Strong Growth, But Patent Cliff Getting Closer (NYSE:ABBV) | Seeking Alpha
7.8% of JDOC
Seeking Alpha · 27 Oct 2026, 22:08 UTC
Novo Nordisk Vs. Eli Lilly Q3 Preview: I'd (Now) Buy Both, But Lilly Is My Top Pick (NVO) | Seeking Alpha
10.4% of JDOC
Seeking Alpha · 28 Oct 2026, 13:49 UTC
UnitedHealth: Raised Premiums, Market Exits And Member Attrition Deliver Future Resilience | Seeking Alpha
5.8% of JDOC
TheStreet · 28 Oct 2026, 19:33 UTC
Breakthrough cancer vaccine catches Wall Street's attention
4.8% of JDOC
Business Insider · 28 Oct 2026, 00:00 UTC
Bye bye Ozempic: Eli Lilly says its new drug retatrutide more than doubles weight loss
7.8% of JDOC